HCPCS Code Q9967

Quick Reference: Q9967

• What it represents: Low-osmolar iodinated contrast in the 300-399 mg iodine/mL concentration band, reported per mL administered (each unit = 1 mL).
• Where it is usually payable: Under Medicare, Q9967 is typically paid separately only in the non-facility/professional setting and priced using ASP-based methodology; payment behavior differs in facility environments due to packaging policies.
• Facility packaging: In many hospital outpatient contexts, contrast supply codes are treated as packaged (reported for tracking/costing but not paid separately), consistent with CMS excluded/packaging lists.
• Commercial payer alignment: Many commercial plans follow a similar approach: contrast is often reimbursed in the office setting but bundled in facility claims; plan-specific rules should be checked, including "professional claim" requirements and timing allowances.
• Audit protection: Document agent name, concentration, route, and exact mL used. Link the claim to diagnoses that justify the contrast-enhanced study and document risk/history when relevant (e.g., contrast allergy history references in CMS radiology guidance).

1. HCPCS Q9967 Definition and Clinical Use

HCPCS Q9967 is defined as "Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml". This definition matters because Q9967 is not a procedure code; it is a supply code that describes the contrast agent category. and the way it is billed. Each billable unit equals one milliliter of contrast administered. In a compliant claim, the unit count should match the documented contrast volume actually given to the patient.

Clinically, Q9967 is used when iodinated, low-osmolar contrast is administered for imaging studies that require intravascular enhancement.

The most familiar settings include contrast-enhanced CT examinations and CT angiography protocols, and it may also appear with other contrast-requiring radiology services when iodinated contrast is used. A key operational point is that Q9967 is driven by the concentration band (300-399 mg iodine/mL) rather than the brand name alone.

Many common nonionic agents are manufactured in multiple concentrations; a facility can stock the same agent in a lower or higher iodine concentration. Billing should reflect the concentration band used for that specific exam, not a "standard" code chosen by habit.

In practice, contrast manufacturers and reimbursement resources often instruct billing Q9967 by matching the mL used on the exam protocol.

For example, Bracco's reimbursement guidance describes reporting the Q-code with the exact number of milliliters administered for CT protocols and highlights that the quantity is not estimated; it should be documented and billed precisely.

That guidance is consistent with payer claim review behavior: if a claim shows an unusually high volume or a round-number volume that conflicts with the protocol or the chart, it is more likely to be flagged for additional documentation.

Compliance anchor: Q9967 is a per-mL supply code. Units should match charted administration records (MAR), contrast logs, or radiology reports (depending on local workflow). If the record documents 95 mL but the claim bills 100 units, the discrepancy is straightforward for an auditor to identify.

2. Practical Comparison: Concentration Bands and Common Coding Pitfalls

Although Q9967 is frequently discussed alongside neighboring Q-codes, the most important real-world distinction is the iodine concentration band. Low-osmolar iodinated contrast codes exist in more than one concentration category, and selecting the wrong category can create internal inconsistency when a payer requests records. The safest method is to map each stocked contrast product (and concentration) to the appropriate HCPCS Q-code in the chargemaster and in any office billing system, then verify mapping during annual coding updates.

Concentration band logic for Q9967

Q9967 is for 300-399 mg iodine/mL products. If the practice uses a 370 mg iodine/mL formulation for CT abdomen/pelvis, Q9967 is generally the correct supply code category. If the practice uses a lower concentration band for a different protocol, the supply code should reflect that. Because a single agent may exist at different concentrations, "agent name only" is not sufficient to pick the correct Q-code; concentration must be considered.

Common pitfalls that trigger denials or recoupments

• Misstating units: Billing mL based on "standard protocol" rather than recorded volume. Payers compare claims to documentation in post-payment reviews.
• Billing in packaged settings expecting separate payment: Hospitals may report Q9967 for cost tracking, but CMS packaging/exclusion rules can prevent separate payment in certain outpatient contexts.
• Double-billing contrast administration: Separately billing an injection/infusion service when it is considered inherent to the imaging service can cause bundling denials. NCCI guidance is commonly referenced during these disputes.
• Using contrast codes with non-iodinated contrast exams: Q9967 is iodinated. MRI contrast is billed with different HCPCS codes; mixing categories creates immediate claim inconsistency.

Conceptually, Q9967 is a "how much iodinated contrast was supplied" code. It does not, by itself, prove that the imaging study was reasonable and necessary. That burden is carried by the imaging CPT and diagnosis codes and by the clinical record supporting the decision to use contrast.

3. Medicare and Commercial Billing Policies

Payment rules for Q9967 are driven by the site of service. In broad terms, Medicare Part B tends to treat contrast supplies as separately payable in professional/non-facility claims under ASP-based pricing frameworks, while many hospital outpatient contexts treat contrast as packaged into the primary service and therefore not separately payable. Your operational workflow should distinguish between (1) reporting for internal costing and coding completeness and (2) expecting separate reimbursement.

Medicare: professional (non-facility) behavior

When the imaging service is billed in a professional setting (for example, physician office imaging or an independent diagnostic testing arrangement), contrast may be reported as Q9967 with per-mL units and paid according to Medicare drug/biological supply pricing methodologies. The pricing mechanism is typically reflected in payer policies that describe contrast and radiopharmaceutical materials for professional claims. In these settings, accurate units directly determine payment, so the charted mL volume is a material billing variable.

Medicare: hospital outpatient packaging and excluded service logic

In many hospital outpatient billing models, the contrast supply is treated as packaged and does not receive separate reimbursement.

CMS publishes lists and policy materials that facilities use to determine whether a supply/service is packaged or excluded for separate payment purposes.

Hospitals may still report the Q-code line for tracking, charge capture analytics, and cost reporting, but the payment expectation is different from office billing.

From a compliance standpoint, the key is not whether the line appears, but whether the organization understands the payment status and avoids erroneous appeals based on the assumption that every line item must be paid separately.

Commercial payers: similar structure, plan-specific variations

Commercial payers often align with Medicare concepts but can implement unique edits. A payer may require the contrast code to appear only on a professional claim type, or it may allow contrast billing within a defined window relative to the imaging date of service, as described in professional reimbursement policies.

AmeriHealth medical policy language emphasizes medical necessity and documentation standards around low-osmolar contrast agents and can be used to anticipate review behavior.

In practice, the most common commercial denial patterns for contrast supplies are:

• Bundling edits in facility settings: "Included in the procedure" determinations are common when the imaging is billed under a facility contract.
• Professional claim requirements: Some plans will deny Q9967 when it appears on the wrong claim type or with mismatched POS settings.
• Documentation requests: When high volumes are billed, payers may request MAR/contrast log documentation and the radiology report.

Operational takeaway: Maintain two clear configurations: one for professional/non-facility billing where Q9967 may be payable, and one for facility settings where Q9967 may be reported but packaged. This avoids systematic denials and reduces rework.

flowchart TD
    A[Q9967 Contrast Supply Billed] --> B{Site of Service?}
    B -->|Office / Non-Facility| C[Bill Q9967 with per-mL units]
    B -->|Hospital Outpatient| D{CMS Packaging Rules}
    C --> E[Separately payable under ASP pricing]
    D -->|Packaged| F[Report for tracking only - no separate payment]
    D -->|Not packaged| G[Separately payable]
    E --> H[Document: agent, concentration, route, exact mL]
    F --> H
    G --> H
    H --> I[Link to imaging CPT + supporting ICD-10 dx]

4. Documentation Requirements for Contrast Use

Because Q9967 payment can be volume-driven (especially in office/professional settings), documentation is not a formality; it is the primary defense in audits and appeals.

At a minimum, documentation should establish: (1) what agent was used, (2) what concentration it was, (3) how much was administered in mL, (4) route (typically IV), and (5) why contrast was appropriate for the clinical question.

AmeriHealth policy language explicitly emphasizes that the record must support medical necessity for the contrast-enhanced service.

What payers commonly look for

• Contrast administration record: A contrast log or MAR entry with volume (mL) and agent identification.
• Radiology report language: "With intravenous contrast" and (ideally) the administered volume and concentration if included in local templates.
• Pre-contrast screening: Documentation of renal function assessment or screening questions where required by local protocol.
• Reaction history: If the patient has a prior contrast reaction or allergy, CMS radiology guidance encourages documentation and coding capture of that history in the record.

A practical "best practice" is to standardize a contrast documentation block in radiology workflows, so the same elements appear consistently. This is especially useful when billing occurs outside the radiology department (for example, centralized professional billing teams) and depends on structured chart fields rather than narrative text.

5. ICD-10 Support and Medical Necessity

Q9967 does not carry medical necessity by itself; it inherits necessity from the underlying imaging service and the patient's clinical indication.

Therefore, correct ICD-10 selection should focus on the condition or symptom prompting the contrast-enhanced exam. For many payers, the decision to use contrast is considered integral to the ordered exam, but if an audit questions contrast usage, the clinical rationale should be evident in the record (for example, lesion characterization, vascular evaluation, staging, or assessing complications).

Radiology coding guidance for CT abdomen/pelvis coding emphasizes correct code selection for exam type and contrast status and provides examples that illustrate how "with contrast" and combined studies are reported.

Diagnosis coding principles that reduce payer friction

• Use the most specific diagnosis available: Avoid relying solely on vague symptom codes when the ordering provider has a working diagnosis or known malignancy/infection.
• Reflect the reason contrast was needed: For example, "rule out abscess," "evaluate mass," or "CTA for suspected aneurysm" should be reflected in the assessment and mapped to diagnosis codes appropriately.
• Capture relevant history affecting contrast decision-making: CMS guidance supports recording and coding relevant history such as prior adverse reactions when applicable.

In appeals, it is often helpful to quote or reference the clinical question from the order (e.g., "evaluate for PE," "characterize hepatic lesion," "assess for bowel ischemia"), because it explains why contrast-enhanced imaging (and therefore contrast supply coding) was clinically appropriate.

6. Modifier Use and Injection Coding Interaction

Q9967 itself typically does not require modifiers such as RT/LT because it is a per-mL supply code without laterality. Most modifier issues occur in the interaction between (1) the imaging code, (2) the contrast supply (Q9967), and (3) any separate injection/administration services that might be billed.

The NCCI Policy Manual is commonly used as an authority for understanding when additional services are considered integral to a primary procedure versus separately reportable.

When modifier -59 becomes relevant

If a provider bills a separate injection administration CPT on the same day as imaging, the claim may be subject to bundling edits.

In some clinical circumstances, payer guidance and coding policy allow a distinct-service modifier (often -59) to indicate that an injection service was separate and not inherent to the imaging encounter, but this is highly payer- and scenario-specific. When disputes occur, payers frequently reference correct coding policy principles regarding bundled services.

Recommended approach to avoid "avoidable" denials

• Confirm whether your payer expects separate billing for injection administration: Many scenarios treat administration as bundled into the imaging service.
• Use -59 only when documentation supports a distinct service: "Distinct" should be demonstrable (separate encounter, separate clinical intent, or separate service not inherent to the imaging code).
• Avoid modifier "spray": Adding modifiers to supply lines without a clear policy basis can increase audit risk rather than reduce denials.

7. Payer Frequency, Timing, and Prior Authorization

Contrast supplies generally do not have independent prior authorization requirements; authorization is typically tied to the imaging exam. However, payer policies may include timing allowances for when contrast codes can be billed relative to the imaging date of service.

For example, professional reimbursement policies may outline whether contrast may appear on a claim dated shortly before the imaging exam under certain billing workflows.

If your organization uses separate scheduling/billing dates (e.g., contrast supplied on one date and imaging performed on another due to workflow), ensure your billing aligns to payer rules.

Frequency limits are also usually driven by the imaging exam rather than by Q9967 itself, but high utilization patterns can still trigger review.

If a patient has multiple contrast-enhanced exams in a short period, the record should clearly show why repeated imaging was clinically necessary, and it should document contrast volumes separately for each encounter.

8. NCCI Edits and Bundling Risk

Because Q9967 is a supply code, it is not typically the central focus of NCCI procedure-to-procedure edits in the same way that CPT procedure codes are.

The bundling risk is usually indirect: it arises when other services (especially injection/administration CPT codes or multiple imaging studies) are billed in a way that conflicts with coding policy.

The CMS NCCI Policy Manual (radiology-related content is commonly located in the radiology chapter) provides the framework payers use when evaluating whether a service is integral to another service.

High-yield bundling risk areas

• Separate injection administration codes: Often bundled into imaging unless a distinct-service rationale exists, and payers may require modifiers and documentation consistent with NCCI principles.
• Multiple CT studies same day: Correct selection of combined codes and correct use of distinct-service modifiers (where appropriate) is critical. Radiology coding guidance for abdomen/pelvis CT explains how combined codes are used and how coding changes when multiple regions or phases are imaged.
• Facility packaging misunderstandings: In hospital outpatient contexts, packaging/exclusion lists inform why a contrast line may not be separately payable.

A practical internal control is to run denial analytics specifically for claims where Q9967 is present. Often the denial reason is not "Q9967 is wrong," but rather a related procedure or modifier conflict. Fixing the upstream workflow usually reduces Q9967-related denials.

9. Billing Scenarios with Imaging Codes

The following scenarios are designed to mirror common billing patterns and show how Q9967 is used as a volume-based supply line while the imaging CPT and diagnoses carry medical necessity. Because payer rules vary, treat these as structure examples rather than universal payment guarantees.

Scenario 1: Office-based CT abdomen/pelvis with IV contrast

Clinical context: Abdominal pain with concern for inflammatory or obstructive process. Imaging: CT abdomen/pelvis performed with IV contrast (CPT selection depends on exact protocol and whether "with" or "with/without" applies). Radiology coding guidance describes how abdomen/pelvis CT codes are selected based on region and contrast status. Contrast: 95 mL of low-osmolar iodinated contrast in the 300-399 mg iodine/mL band. Billing structure: Imaging CPT + Q9967 x 95 units. Keep the contrast volume tied to the charted record and protocol; Bracco's guidance emphasizes matching billed units to the mL administered.

Scenario 2: Hospital outpatient CT with contrast (packaged supply)

Clinical context: Same type of CT performed in a hospital outpatient department. Billing structure: Hospital outpatient claim reports the imaging service and may list Q9967 for tracking; separate reimbursement may be affected by CMS packaging/exclusion policy logic in outpatient payment frameworks. Operational implication: The line may appear on the claim, but payment expectations should be aligned with packaging rules to prevent unnecessary appeal volume.

Scenario 3: High-volume contrast triggers documentation request

Clinical context: A complex CTA protocol requiring higher total mL due to multi-phase acquisition. Billing structure: Imaging CPT + Q9967 with the exact high mL unit count. Documentation focus: Include protocol justification and contrast log entry with agent, concentration, and total mL. If a payer questions necessity, the record should show why multi-phase imaging was required and how contrast supported the clinical question, consistent with the medical necessity emphasis in payer policy.

Scenario 4: Patient history of reaction affects charting and coding

Clinical context: Patient reports prior iodinated contrast reaction; enhanced imaging still clinically indicated after risk mitigation. Billing structure: Imaging CPT + Q9967 (units match administered mL). Documentation focus: Record the reaction history, screening, and mitigation steps. CMS radiology guidance highlights the importance of capturing relevant history and appropriate documentation practices in radiology services.

Scenario 5: Denial due to bundled administration code

Clinical context: Office bills separate injection administration code in addition to imaging and Q9967. Denial pattern: Injection/administration code denied as bundled into imaging per payer edits referencing correct coding principles. Resolution strategy: Evaluate whether administration is separately billable for that payer and scenario and whether documentation supports a distinct service, consistent with NCCI-based bundling frameworks. Q9967 itself may be correct; the denial is often driven by the accompanying procedure coding.

Across all scenarios, the most defensible Q9967 billing shares the same features: mL units match documentation, the imaging CPT matches the protocol, diagnoses support the reason for the study, and any additional services are billed in a manner consistent with payer coding policy and bundling frameworks.